EBMT 2018 | EBMT 2018 overview: AML pathophysiology
Antonio Almeida, MD, PhD, of the Instituto Português de Oncologia Francisco Gentil, Lisbon, Portugal, gives an overview of acute myeloid leukemia (AML) pathophysiology at the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal.
Transcript (edited for clarity)
Well the main idea of this session is to look deeply into the pathophysiology of AML, of how clonal evolution happens in AML, how we can monitor clonal evolution, and then how we can target it in terms of treatment. So we’re going to have three speakers. The first speaker is going to look at clonal evolution: all the mechanisms, why cells in AML evolve, and why these clones become resistant to therapy and why different therapies are needed...
Well the main idea of this session is to look deeply into the pathophysiology of AML, of how clonal evolution happens in AML, how we can monitor clonal evolution, and then how we can target it in terms of treatment. So we’re going to have three speakers. The first speaker is going to look at clonal evolution: all the mechanisms, why cells in AML evolve, and why these clones become resistant to therapy and why different therapies are needed. The second speaker, who’s from Italy, will be talking about monitoring of clones in AML, and detection of small clones, and how these clones will then evolve into relapse in patients. And I will be doing the final talk, looking very much into the future of how we can target these remaining clones and patients who are in remission with maintenance therapy to try and delay or avoid if possible relapses in various situations post-induction and even post-transplant.
Read more...
